If FXR is indeed regulating Sqstm1/p62 expression for these processes, then tissue-specific drug development of a synthetic activator of FXR in the intestine could be beneficial for treating or preventing intestinal diseases. This evidence concerns the gene NR1H4 and intestinal disorder.